Should You Buy Apellis Pharmaceuticals Inc (APLS) Today? Analysis, Price Targets, and 2026 Outlook.
No data
No data
Growth
Profitability
Efficiency
Wall Street analysts forecast APLS stock price to fall
14 Analyst Rating
Wall Street analysts forecast APLS stock price to fall
9 Buy
5 Hold
0 Sell
Moderate Buy
Current: 41.030
Low
19
Averages
31.69
High
48
Current: 41.030
Low
19
Averages
31.69
High
48
Wells Fargo
Derek Archila
Overweight -> Equal Weight
downgrade
$26 -> $41
AI Analysis
2026-04-17
Reason
Wells Fargo
Derek Archila
Price Target
$26 -> $41
AI Analysis
2026-04-17
downgrade
Overweight -> Equal Weight
Reason
As previously reported, Wells Fargo analyst Derek Archila downgraded Apellis (APLS) to Equal Weight from Overweight with a price target of $41, up from $26. The firm is moving to the sidelines following Biogen's (BIIB) announced acquisition of the company. Wells expects the deal to close in Q2 2026.
Wells Fargo
Overweight -> Equal Weight
downgrade
$26 -> $41
2026-04-17
Reason
Wells Fargo
Price Target
$26 -> $41
2026-04-17
downgrade
Overweight -> Equal Weight
Reason
Wells Fargo downgraded Apellis to Equal Weight from Overweight with a price target of $41, up from $26.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for APLS
